Results indicate Amgen's denosumab originally developed for osteoporosis helps with bone health in women with advanced breast cancer as well. NYT reported the info yesterday. http://www.nytimes.com/2009/07/08/business/08amgen.html?partner=rss&emc=... The prior major report we had on this drug was from 2008 and showed similar efficacy to conventional bisphosphonates. http://clincancerres.aacrjournals.org/cgi/content/abstract/14/20/6690 So far there is no new paper on the denosumab so it's a bummer Amgen chose to release its new results in a press release instead of in a peer-reviewed journal. Dr. Roger Perlmutter is quoted with a enthusiastic statement which has yet to be reviewed by his peers or the FDA. Part of what distinguishes us from the herbalists and the snake oil salesmen is the peer review process: the idea that we subject our ideas to outside review by experts. Amgen and many other drug companies have been circumventing this process by describing their results in press releases. Shares of Amgen were up over $7 on the news today which means a $7 billion increase to the market cap overnight. Now we understand why these results are reported the way they are. Let's hope doctors are reading press releases.